287 related articles for article (PubMed ID: 34050837)
1. MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli Population.
Ben Shachar S; Barda N; Manor S; Israeli S; Dagan N; Carmi S; Balicer R; Zisser B; Louzoun Y
J Clin Immunol; 2021 Aug; 41(6):1154-1161. PubMed ID: 34050837
[TBL] [Abstract][Full Text] [Related]
2. HLA repertoire of 115 UAE nationals infected with SARS-CoV-2.
Alnaqbi H; Tay GK; Jelinek HF; Francis A; Alefishat E; El Haj Chehadeh S; Tahir Saeed A; Hussein M; Laila Salameh ; Mahboub BH; Uddin M; Alkaabi N; Alsafar HS;
Hum Immunol; 2022 Jan; 83(1):1-9. PubMed ID: 34462158
[TBL] [Abstract][Full Text] [Related]
3. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19.
Fischer JC; Schmidt AG; Bölke E; Uhrberg M; Keitel V; Feldt T; Jensen B; Häussinger D; Adams O; Schneider EM; Balz V; Enczmann J; Rox J; Hermsen D; Schulze-Bosse K; Kindgen-Milles D; Knoefel WT; van Griensven M; Haussmann J; Tamaskovics B; Plettenberg C; Scheckenbach K; Corradini S; Pedoto A; Maas K; Schmidt L; Grebe O; Esposito I; Ehrhardt A; Peiper M; Buhren BA; Calles C; Stöhr A; Lichtenberg A; Freise NF; Lutterbeck M; Rezazadeh A; Budach W; Matuschek C
Eur J Med Res; 2021 Sep; 26(1):107. PubMed ID: 34530915
[TBL] [Abstract][Full Text] [Related]
4. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience.
Littera R; Campagna M; Deidda S; Angioni G; Cipri S; Melis M; Firinu D; Santus S; Lai A; Porcella R; Lai S; Rassu S; Scioscia R; Meloni F; Schirru D; Cordeddu W; Kowalik MA; Serra M; Ragatzu P; Carta MG; Del Giacco S; Restivo A; Deidda S; Orrù S; Palimodde A; Perra R; Orrù G; Conti M; Balestrieri C; Serra G; Onali S; Marongiu F; Perra A; Chessa L
Front Immunol; 2020; 11():605688. PubMed ID: 33343579
[TBL] [Abstract][Full Text] [Related]
5. HLA-C*04:01 Affects HLA Class I Heterozygosity and Predicted Affinity to SARS-CoV-2 Peptides, and in Combination With Age and Sex of Armenian Patients Contributes to COVID-19 Severity.
Hovhannisyan A; Madelian V; Avagyan S; Nazaretyan M; Hyussyan A; Sirunyan A; Arakelyan R; Manukyan Z; Yepiskoposyan L; Mayilyan KR; Jordan F
Front Immunol; 2022; 13():769900. PubMed ID: 35185875
[TBL] [Abstract][Full Text] [Related]
6. Association between HLA genotypes and COVID-19 susceptibility, severity and progression: a comprehensive review of the literature.
Migliorini F; Torsiello E; Spiezia F; Oliva F; Tingart M; Maffulli N
Eur J Med Res; 2021 Aug; 26(1):84. PubMed ID: 34344463
[TBL] [Abstract][Full Text] [Related]
7. Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients.
Kwon OJ; Brautbar C; Weintrob N; Sprecher E; Saphirman C; Bloch K; Pinhas-Hamiel O; Assah S; Vardi P; Israel S
Hum Immunol; 2001 Jan; 62(1):85-91. PubMed ID: 11165718
[TBL] [Abstract][Full Text] [Related]
8. HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity.
Amoroso A; Magistroni P; Vespasiano F; Bella A; Bellino S; Puoti F; Alizzi S; Vaisitti T; Boros S; Grossi PA; Trapani S; Lombardini L; Pezzotti P; Deaglio S; Brusaferro S; Cardillo M;
Transplantation; 2021 Jan; 105(1):193-200. PubMed ID: 33141807
[TBL] [Abstract][Full Text] [Related]
9. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews.
Kwon OJ; Karni A; Israel S; Brautbar C; Amar A; Meiner Z; Abramsky O; Karussis D
Arch Neurol; 1999 May; 56(5):555-60. PubMed ID: 10328250
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection.
Fischer JC; Balz V; Jazmati D; Bölke E; Freise NF; Keitel V; Feldt T; Jensen BO; Bode J; Lüdde T; Häussinger D; Adams O; Schneider EM; Enczmann J; Rox JM; Hermsen D; Schulze-Bosse K; Kindgen-Milles D; Knoefel WT; van Griensven M; Haussmann J; Tamaskovics B; Plettenberg C; Scheckenbach K; Corradini S; Pedoto A; Maas K; Schmidt L; Grebe O; Esposito I; Ehrhardt A; Peiper M; Buhren BA; Calles C; Stöhr A; Gerber PA; Lichtenberg A; Schelzig H; Flaig Y; Rezazadeh A; Budach W; Matuschek C
Eur J Med Res; 2022 Nov; 27(1):255. PubMed ID: 36411478
[TBL] [Abstract][Full Text] [Related]
11. The Influence of HLA Polymorphisms on the Severity of COVID-19 in the Romanian Population.
Vică ML; Dobreanu M; Curocichin G; Matei HV; Bâlici Ș; Vușcan ME; Chiorean AD; Nicula GZ; Pavel Mironescu DC; Leucuța DC; Teodoru CA; Siserman CV
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279325
[TBL] [Abstract][Full Text] [Related]
12. HLA alleles associated with susceptibility and severity of the COVID-19 in Vietnamese.
Hai NTT; Nhung VP; Tam NTT; Ngoc TTB; Thuong MTH; Dai HV; Duong NT; Hai NV; Ton ND; Thach PN; Ha NH
Hum Immunol; 2024 May; 85(3):110796. PubMed ID: 38580537
[TBL] [Abstract][Full Text] [Related]
13. HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease.
Hosseini E; Minagar A; Ghasemzadeh M; Arabkhazaeli A; Ghasemzadeh A
Hum Immunol; 2023 Apr; 84(4):263-271. PubMed ID: 36822912
[TBL] [Abstract][Full Text] [Related]
14. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection.
Littera R; Chessa L; Deidda S; Angioni G; Campagna M; Lai S; Melis M; Cipri S; Firinu D; Santus S; Lai A; Porcella R; Rassu S; Meloni F; Schirru D; Cordeddu W; Kowalik MA; Ragatzu P; Vacca M; Cannas F; Alba F; Carta MG; Del Giacco S; Restivo A; Deidda S; Palimodde A; Congera P; Perra R; Orrù G; Pes F; Loi M; Murru C; Urru E; Onali S; Coghe F; Giglio S; Perra A
PLoS One; 2021; 16(8):e0255608. PubMed ID: 34352002
[TBL] [Abstract][Full Text] [Related]
15. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China.
Trachtenberg E; Vinson M; Hayes E; Hsu YM; Houtchens K; Erlich H; Klitz W; Hsia Y; Hollenbach J
Tissue Antigens; 2007 Dec; 70(6):455-63. PubMed ID: 17900288
[TBL] [Abstract][Full Text] [Related]
16. Frequency of HLA alleles among COVID-19 infected patients: Preliminary data from Saudi Arabia.
Naemi FMA; Al-Adwani S; Al-Khatabi H; Al-Nazawi A
Virology; 2021 Aug; 560():1-7. PubMed ID: 34015620
[TBL] [Abstract][Full Text] [Related]
17. A single center study of protective and susceptible HLA alleles and haplotypes with end-stage renal disease in China.
Pan Q; Ma X; Chen H; Fan S; Wang X; You Y; Wang Z; Sun L; Zhao X; Shen J; Tan R; Gong G; Gu M
Hum Immunol; 2019 Nov; 80(11):943-947. PubMed ID: 31521393
[TBL] [Abstract][Full Text] [Related]
18. Association between the HLA genotype and the severity of COVID-19 infection among South Asians.
Naemi FMA; Al-Adwani S; Al-Khatabi H; Al-Nazawi A
J Med Virol; 2021 Jul; 93(7):4430-4437. PubMed ID: 33830530
[TBL] [Abstract][Full Text] [Related]
19. Association of HLA-B22 serotype with SARS-CoV-2 susceptibility in Hong Kong Chinese patients.
Yung YL; Cheng CK; Chan HY; Xia JT; Lau KM; Wong RSM; Wu AKL; Chu RW; Wong ACC; Chow EYD; Yip SF; Leung JNS; Lee CK; Ng MHL
HLA; 2021 Feb; 97(2):127-132. PubMed ID: 33179437
[TBL] [Abstract][Full Text] [Related]
20. MHC Variants Associated With Symptomatic
Castelli EC; de Castro MV; Naslavsky MS; Scliar MO; Silva NSB; Andrade HS; Souza AS; Pereira RN; Castro CFB; Mendes-Junior CT; Meyer D; Nunes K; Matos LRB; Silva MVR; Wang JYT; Esposito J; Coria VR; Bortolin RH; Hirata MH; Magawa JY; Cunha-Neto E; Coelho V; Santos KS; Marin MLC; Kalil J; Mitne-Neto M; Maciel RMB; Passos-Bueno MR; Zatz M
Front Immunol; 2021; 12():742881. PubMed ID: 34650566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
